Results showed a significant improvement in erectile function scores among those treated with Sildigra 100 Mg compared to placebo, suggesting its potential as a viable treatment option. Similarly, a meta-analysis by [Research Team] pooled data from multiple studies examining PDE5 inhibitors in liver cirrhosis patients. While the analysis encompassed various medications within this class, including Sildenafil (the active ingredient in Sildigra), findings consistently demonstrated improvements in erectile function and overall sexual satisfaction with PDE5 inhibitor therapy.